Axon Enterprise Inc vs Lemonade Inc — how do they compare? Axon Enterprise Inc trades at $555.95 (market cap $44.11B), while Lemonade Inc trades at $71.36 (market cap $5.39B). The key difference: Axon Enterprise Inc is far larger — about 8.2× Lemonade Inc's market cap, and Lemonade Inc is trading nearer its 52-week high, Axon Enterprise Inc nearer its low. Which is the better fit depends on your goals.
| AXON | LMND | |
|---|---|---|
Market Cap | $44.11B | $5.39B |
Sector | Technology | Financials |
52-Week High | $870.97 | $96.57 |
52-Week Low | $345.94 | $36.28 |
Enterprise Value | $45.20B | $5.21B |
Signals from Pluang's Aura AI — not financial advice
Axon Enterprise (AXON) trades at $547.03, down 3.32% on the day, with strong analyst support (81% buy ratings) and a consensus price target of $648.67. The stock shows bullish technical signals with support at $539 and resistance at $553. Recent earnings have been mixed with Q3 2025 missing estimates but Q4 2025 and Q1 2026 beating expectations. Revenue growth remains solid with 2026 projections at $3.0B and net profit margin improving to 6.9%.
Axon presents growth potential driven by strong demand for connected devices and software services, though elevated valuation ratios (P/E 220.67) pose risk. Positive sentiment stems from recent upgrades and institutional interest, including notable insider buying. Key risks include execution challenges and competitive pressures in the law enforcement technology sector.
Lemonade (LMND) trades at $70.62, up 0.16% on the day, with a bullish technical signal from moving averages and ADX indicators. Revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, while net losses are narrowing, with the net margin improving from -116.02% to -22.43% over the same period. Recent news highlights expansion into new states and a renegotiated reinsurance program, improving cost structure and capital efficiency.
The outlook is mixed; strong revenue growth and narrowing losses present a long-term opportunity, but the stock trades above the consensus price target of $67.00, with 40% of analysts rating it a sell. Key risks include persistent unprofitability, high valuation multiples, and execution challenges in scaling the AI-driven insurance model. Positive cash flow from operations is projected for 2026, a potential inflection point.
Trailing returns across standard periods
Latest headlines on both assets
Axon develops technology and weapons for law enforcement and military use. Its ecosystem includes TASER devices, body cameras, and Evidence.com, a cloud-based platform for digital evidence management.
Read more on AXON →Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →